Development of a cell therapy set prototype for autologous iPS cells

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Biotechnology

Background:

• Autologous cell therapy using induced pluripotent stem cells (iPSCs) offers reduced immune rejection.
• Current GMP-compliant iPSC production is labor-intensive and not suited for custom autologous manufacturing.
• A simplified, closed-system approach is needed for efficient autologous iPSC production.

Purpose of the Study:

• To develop a closed culture system for producing therapeutic cells from patient-derived iPSCs.
• To create a scalable and efficient manufacturing process for autologous iPSC-based cell therapies.
• To enable custom manufacturing of autologous iPSCs with simplified aseptic operations.

Main Methods:

• A closed culture kit with 10 interconnected culture ports (small cell culture bags) was developed.
• Cells were transferred between ports for sequential processing steps including vector infection, iPSC establishment, proliferation, and differentiation induction.
• Atelocollagen beads were used to facilitate cell movement and prevent detachment during processing.

Main Results:

• The closed system successfully reproduced a series of iPSC derivation and differentiation processes.
• Pilot studies demonstrated the feasibility of establishing iPSCs on atelocollagen beads from PBMCs.
• Differentiated cells (cardiomyocytes, pancreatic progenitors, dopaminergic neurons) were generated, and their marker expression was evaluated.

Conclusions:

• A closed culture system was successfully established for the reproducible processing of iPSCs and their differentiated progeny.
• The use of atelocollagen beads facilitated cell handling within the closed system.
• This system shows potential for simplified, efficient autologous iPSC manufacturing for cell therapy.